Skip to content

Advertisement

Cancer Cell International

What do you think about BMC? Take part in

Open Access

ABC transporters as multidrug resistance mechanisms and the development of chemosensitizers for their reversal

Cancer Cell International20055:30

https://doi.org/10.1186/1475-2867-5-30

Received: 20 March 2004

Accepted: 04 October 2005

Published: 04 October 2005

Abstract

One of the major problems related with anticancer chemotherapy is resistance against anticancer drugs. The ATP-binding cassette (ABC) transporters are a family of transporter proteins that are responsible for drug resistance and a low bioavailability of drugs by pumping a variety of drugs out cells at the expense of ATP hydrolysis. One strategy for reversal of the resistance of tumor cells expressing ABC transporters is combined use of anticancer drugs with chemosensitizers. In this review, the physiological functions and structures of ABC transporters, and the development of chemosensitizers are described focusing on well-known proteins including P-glycoprotein, multidrug resistance associated protein, and breast cancer resistance protein.

Keywords

ABC transporterbioavailabilitychemosensitizerdrug resistanceP-glycoproteinmultidrug resistance associated proteinbreast cancer resistance protein.

Background

One of the major problems related with anticancer chemotherapy is resistance against anticancer drugs. Some cancers such as non-small cancer, lung cancer, and rectal cancer show what is called primary resistance or natural resistance in which they do not respond to standard chemotherapy drugs from the beginning. On the other hand, many types of sensitive tumors respond well to chemotherapy drugs in the beginning but show acquired resistance later. Experimentally, drug resistance could be very specific to the drug used due to abnormal genetic machinery such as gene amplification within tumor cells in many cases. Multidrug resistance (MDR) is especially problematic in acquired drug resistance. MDR is the phenomenon in which cancer cells exposed to one anticancer drug show resistance to various anticancer drugs that are structurally and functionally different from the initial anticancer drug. The most investigated mechanisms with known clinical significance are: a) activation of transmembrane proteins effluxing different chemical substances from the cells; b) activation of the enzymes of the glutathione detoxification system; c) alterations of the genes and the proteins involved into the control of apoptosis (especially p53 and Bcl-2). The cell membrane, cytoplasm, and nuclear protein participate in these resistance mechanisms [1]. The resistance mechanism is called typical MDR or classical MDR when overexpression of the membrane efflux pumps is involved in MDR. The classical MDR is due mostly to increased efflux pumps in the cell membrane of cells pumping anticancer drugs out of cells. The most typical efflux pumps in the cell membrane is P-glycoprotein (Pgp) [2] having the molecular weight of 170 KD, due to the gene amplification of the normal human gene, MDR1. The efflux pump Pgp is responsible for transporting various xenobiotics (not limited to anticancer drugs) out of cells by using ATP (Fig. 1) [3]. Pgp is one of the membrane transporter superfamily having the ATP-binding cassette (ABC) with well-preserved homology of the site where ATP binds. There are more than 100 ABC transporters distributed from prokaryotes to humans. Forty-eight ABC genes have been reported in humans, among which the functions of 16 genes have been determined and 14 genes are related with diseases present in humans (cystic fibrosis, adrenoleukodystrophy, Stargardt's disease, drug-resistant tumors, Dubin-Johnson syndrome, Byler's disease, progressive familiar intrahepatic cholestasis, X-linked sideroblastic anemia, ataxia, and persistent and hyperinsulimenic hypoglycemia in children) http://www.nutrigene.4t.com/humanabc.htmc[4, 5].
Figure 1

Schematic structural organization of P-glycoprotein. Each half contains a highly hydrophobic domain with 6 transmembrane α-helices involved in chemotherapeutic drug efflux, and a hydrophilic domain located at the cytoplasmic face of the membrane, nucleotide binding domain 1(NBD1) or NMD 2, containing an ATP-binding site with cheracteristic Walker motifs A and B and the S signature of ABC transporters. The two half molecules are separated by a highly charged "linker region which is phosphorylated at several sites by protein kinase C and the first extracellular loop is heavily N-glycosylated [3].

Other efflux pumps of the mammalian cell membrane in ABC superfamily include multidrug resistance-associated proteins (MRP) [6] and breast cancer resistance proteins (BCRP; mitoxantrone resistance proteins, MXR) [7, 8]. Other than the fact that these resistant proteins belong to the ABC superfamily, they are quite different with respect to gene locus, amino acid sequence, structure and substrate (Table 1 and 2). In this review, the physiological functions and structures of ABC transporters, and development of chemosensitizers are described focusing on well-known proteins including Pgp, MRP, and BCRP.
Table 1

Gene locus and tissue distribution of ABC transporters

Name

Alternate name

Gene locus

Tissue distribution

MDR1

ABCB1, P-GP

7q36 [9]

Gut (apical membrane), liver (canalicular membrane), kindey (apical membrane of epithelial cells of proximal tubule), blood brain barrier (luminal membrane of endothelial cells), testis (endothelial cells of capillary), placenta (trophoblast)

MRP1

ABCC1

16p13.1 [6]

Many tissues (brain etc)

MRP2

ABCC2, cMOAT

10q24 [10]

Liver, gut, kidney, placenta

MRP3

ABCC3

17q21.3 [11]

Liver, gut, adrenal cortex, placenta

MRP4

ABCC4

13q32 [11]

Many tissues

MRP5

ABCC5

3q27 [11]

Many tissues(brain etc)

MRP6

ABCC6

16p13.1 [12]

Liver, kidney

MRP7

ABCC10

6p12-21 [13]

Many tissues

MRP8

ABCC11

16q12.1 [14]

Breast, testes

BCRP

ABCG2, MXR1, ABCP

4q22 [15]

Placenta (syncytiotrophoblasts), intestine (epithelium), liver (canalicular membrane), breast (ducts and lobules), endometrium (vein and capillary but not artery), gut

Table 2

Endogenous and exogenous substrates for ABC transporters

Name

Endogenous substrate

Exogenous cytotoxic substance

MDR1

Estrogen glucuronide conjugates (estradiol, estriol), endorphin, glutamate, steroids (cortisol, aldosterone, corticosterone), beta-amyloid, 1-O-alkyl-2-acetyl-sn-glycero-3-phosphocholine (generically platelet-activating factor, PAF)

Anthracyclines (doxorubucin, daunorubicin, epirubicin), actinomycin D, colchicine, podophyllotoxin (etoposide, teniposide), methotrexate (only in carrier-deficient cells), mitomycin C, mitoxantrone, taxenes (paclitaxel, docetaxel), vinca alkaloids (vincristine, vinblastine)

MRP1

Estradiol-17beta(beta-D-glucuronide) glutathione, glutathione S-conjugate leukoetriene C4, glucuronosyl bilirubin

Anthracyclines, cochicine, etoposide, heavy metals (arsenite, arsenate, antimonials), vincristine, vinblastine, paclitaxel

MRP2

Estradiol-17beta(beta-D-glucuronide), glutathione, glutathione S-conjugate Leukoetriene C4, glucuronosyl bilirubin,

Cisplatin, CPT-11, doxorubicin, etoposide, methotrexate, SN-38, vincristine, vinblastine

MRP3

S-(2,4-dinitrophenyl)glutathione

Cisplatin, doxorubicin, etoposide, methotrexate, teniopside, vincristine,

MRP4

Glucuronide and glutathione conjugates

Methotrexate, nucleotide analogs, PMEA*

MRP5

Glutamate and phosphate conjugates

Doxorubicin, methotrexate, nucleotide analogs, topotecan,

MRP6

Cyclic nucleotides (cAMP, cGMP), glutathione conjugate

Doxorubicin, etoposide, teniposide

MRP7

?

?

MRP8

17beta-estradiol-(17-beta-D-glucuronide), leukotriene C4, cyclic nucleotides

5'-Fluorouracil, 5'-fluoro-2'-deoxyuridine, 5'-fluoro-5'-deoxyuridine, PMEA*

BCRP

Heme or porphyrin

Anthracyclines, bisantrene, camptothecin, epirubicin, flavopiridol, mitoxantrone, S-38, topotecan

* PMEA, 2',3'-dideoxycytidine 9'-(2'-hosphonylmethoxynyl)adenine

Functions of ABC transporters

Although the physiologic functions of ABC transporters are not well known, they are expressed constitutively in not only tumor cells but also normal cells in the digestive system including the small intestine, large intestine, liver, and pancreas; epithelial cells in the kidneys, adrenals, brain, and testes; and endothelial cells (Table 1). From the aspect of the tissue distribution, ABC transporters are thought to participate in the absorption and secretion of endogenous and exogenous substances. Endogenous and exogenous substrates for ABC transporters reported so far are summarized in Table 2. Especially, the ABC transporters have shown to function as an efflux pump for lipid, multiple drugs, natural products and peptides. It is proposed to operate as a hydrophobic vacuum cleaner, expelling non-polar compounds from the membrane bilayer to the exterior, driven by the energy of ATP hydrolysis [143]. ATP-dependent transbilayer lipid transporters are classified into cytofacially-directed flippases and exofacially-directed floppases. Floppase activity has been associated with the ABC transporters although not all ABC transporters are floppases [144]. Endogenous substrates for Pgp include corticosterone [145], beta-estradiol 17beta-D-glucuronide, an endogenous cholestatic metabolite of estradiol [146], 1-O-alkyl-2-acetyl-sn-glycero-3-phosphocholine (generically platelet-activating factor, PAF) [147], glutamate [148] and endorphin [149]. It was also recently reported that Pgp has the function of removing beta-amyloid, which was reported as the causal substance of Alzheimer's disease [150, 151]. MRP1 effluxes various conjugated substrates such as leukotriene C4 conjugates [152], steroid conjugates [153] and the GSH conjugate of aflatoxin B1, which is a mycotoxin [154]. Cells can, upon hypoxic demand, use BCRP to reduce heme or porphyrin accumulation, which can be detrimental to cells [155]. When cancer originates not only from cells normally expressing efflux pump but also cells having genes but not expressing, gene expression is initiated due to the exposure to anticancer drugs, resulting in resistance to anticancer drugs, eventually interfering with chemotherapy.

Pgp is mainly present in the apical membrane of intestinal mucosal membrane and lowers bioavailability of drugs by preventing the absorption of the drugs. Digoxin, which shows a low bioavailability and is mainly excreted through stool in normal mice due to poor absorption in the mouse intestine, shows a high bioavailability and mainly excreted through urine in mice with mdr1 knocked out[156]. The bioavailability of the substrate of Pgp, paclitaxel, also increased significantly in mice with mdr1 knocked out and in mice administered with the Pgp inhibitor, PSC-833 [157].

Recently, multiple MDR1 polymorphisms including more than 20 single nucleotide polymorphism (SNP) have been identified. The mutations at positions 2677(G→T) and 2995(G →A) of MDR1 in normal cells were firstly reported [158]. MDR1 polymorphism could be not only associated with alteration of Pgp expression and/or function, drug disposition and treatment outcome but also increase the risk of diseases such as Parkinson's disease and ulcerative colitis [159]. The influence of MDR1 SNP(C3435T and G2677T) on disposition of Pgp substrates or treatment outcome has been examplified in digoxin, phenytoin, fexofenadine, nelfinarvir, cyclosporine, talinolol and loperamide [159]. Polymorphisms of other ABC transporters have been reported [160163].

If a substance in food affects Pgp, this substance also could affect the bioavailability of substrate drugs for Pgp. It was reported that substances present in grape juice or orange juice could increase the bioavailability of a drug being the substrate of Pgp by inhibiting it. [164]. These substances could also affect pharmacokinetics of other drugs [160, 165]. On the contrary, some drugs could increase the expression of Pgp. St John's Wort used as an antidepressant increases the expression of Pgp, so it could significantly lower the serum concentration of indinavir or cyclosporin [166]. Digoxin is the substrate of Pgp and induces paclitaxel resistance by increasing Pgp [166]. Not only Pgp but also MRP and BCRP could affect the bioavailability of drugs.

One of the important physiological functions of efflux pump present in the cell membrane is to provide a pharmacological sanctuary for tissues present in the blood-tissue barriers such as in the case of blood-brain barrier (BBB), blood-placental barrier and blood-testes barrier. Hydrophilic substances present in blood could not go into tissues when they are not small enough to pass through the tight junction with simple diffusion. Nonetheless, various hydrophobic substances could not enter these tissues because they are effluxed out by efflux pumps. Actually, Pgp effluxes neurotransmitters or neuromodulators such as glutamate [148] and opioids [149, 167] into blood from the brain. Compared with wild-type mice, drugs beings the substrate of Pgp were significantly increased in the brain of fetus when the mdr1 gene is knocked out in mice [168171]. When the BCRP inhibitor, GF120918, was introduced to pregnant mice, the topotecan level was increased by two-folds in mouse fetus, suggesting that BCRP would function as the maternal-fetal barrier in the placenta [172]. Thus, quantitative and qualitative changes of transporters present in the membrane could affect pharmacokinetics such as the distribution of endogenous and exogenous substances.

Structure of ABC transporters

Pgp is a 170-kDa membrane protein glycosylated at the first extracellular loop (Fig. 1). Pgp is composed of 12 hydrophobic transmembrane domains (TMDs) and 2 nucleotide-binding domain (NBD). One NBD connects two TMDs with a hydrophilic NBD loop. TDMs form channels for substrate drugs, determine the characteristics of substrate, and efflux substrate drugs whereas NBDs are located in the interior of cytoplasm, and participate in ATP binding and hydrolysis [173]. Pgp undergoes conformational changes upon binding of nucleotide to the NBDs [174]. Rosenberg et al. have analyzed the three-dimensional structures of Pgp and its conformational change in the presence and absence of nucleotide [175177]. The projection of the protein perpendicular to the membrane is roughly rectangular with a maximum depth of 8 nm, a pore size of 2.5 nm and two 3-nm lobes exposed at the cytoplasmic face of the membrane. The conformational change revealed a major reorganization of the TMDs throughout the entire depth of the membrane upon binding of nucleotide (Fig. 2A). In the absence of nucleotide, the two TMDs form a single barrel 5–6 nm in diameter and about 5 nm deep with a central pore that is open to the extracellular surface and spans much of the membrane depth. Upon binding nucleotide, the TMDs reorganize into three compact domains that are each 2–3 nm in diameter and 5–6 nm deep (Fig. 2B). This reorganization opens the central pore along its length in a manner that could allow access of hydrophobic drugs (transport substrates) directly from the lipid bilayer to the central pore of the transporter [176].
Figure 2

Comparison of nucleotide free-Pgp (nf-Pgp) and Pgp-AMP-PNP (Pgp-AMP-PNP) three-dimensional structures. A, stereo pair of the nf-Pgp three-dimensional structure, displayed using netting at 1.0 σ (red) and 1.5 σ (yellow) above the mean density level and viewed perpendicular to the crystal plane from the more heavily stained side (corresponding to the extracellular surface). B, equivalent views of the Pgp-AMP-PNP structure. The arrow indicates the gap along one side of the central pore. The locations of the three discrete densities A, B, and C are indicated. C, stereo pair of a side view of Pgp-AMP-PNP with the same color scheme as above. The directions of the principle crystallographic axes a and b are shown. Scale bar = 2.2 nm. AMP-PNP, non-hydralizable ATP analogue [176].

When one of two NBDs of Pgp is inactivated, not only drug transport but also ATP hydrolysis of normal NBD is inhibited. This result indicates that two NBDs would function cooperatively and they could not hydrolyze ATP independently [178]. It was recently reported that structural changes of NBDs are brought about when a drug binds to TMD so that the distance between NBDs is changed to affect the activity of ATPase as shown in Fig. 3[179]. Unlike in Pgp, however, the substrate leukotriene C4 could not be transported once NBD2 is inactivated but the substrate transport could not be inhibited when NBD1 is inactivated in MRP1 [180]. This result suggests that among ABC transporters, interactions of NBDs are not simple but function differently for every transport. Although the exact site and number of Pgp binding with drugs have not yet been determined, the important binding sites such as TMD 4, 5, 6, 10, 11 and 12 have been determined [181] whereas substrate drugs do not bind to NBDs [182].
Figure 3

Model of the NBD conformational change by the drug binding to TDM. [178].

Development of chemosensitizers to overcome resistance

One of the causes for the failure of chemotherapy in the treatment of cancer is the emergence of MDR. Once MDR appears, chemotherapy is not effective even when using high doses of drugs enough to overcome resistance, toxic effects are brought about and the resistance mechanism could be further stimulated. These problems could be resolved by the use of the anticancer drugs that could bypass the resistance mechanism. For example, we could use other anticancer drugs such as alkylating drugs (cyclophosphamide), antimetabolites (5-fluorouracil), and the anthracycline modified drugs (annamycin and doxorubicin-peptide) that would not function as the substrates of ABC transporters [183185]. The final method of overcoming resistance is to administer substances inhibiting ABC transporters with anticancer drugs at the same time. These substances would reverse resistance against anticancer drugs to eventually being sensitized for anticancer drugs so they are called chemosensitizers. They are also called MDR modulators and MDR reverters. Chemosensitizers against each transporter are summarized according to the publishing years (Table 3). Of these, some are chemosensitizers against one transporter and some others against more than two transporters.

Many drugs such as the calcium channel blocker verapamil and the immunosuppressant cyclosporin A would inhibit resistance by functioning as competitive substrates of Pgp regardless of their innate pharmacological functions. Different clinical studies also showed that these drugs could reverse resistance to anticancer drugs. Verapamil is the first reported chemosensitizer inhibiting MDR [119] and its effect was also proven in the recent clinical study [186]. However, verapamil brings about cardiac toxicity at the concentration inhibiting resistance; thus, in order to resolve this problem, the attempts were made to develop (R)-verapmil [187] and verapamil analogues having lower cardiac toxicity compared with (S)-verapamil [188, 189]. The immunosuppressant cyclosporin A was first reported to reverse resistance by acute leukemia against vincristine and daunorubicin [190]. Following cyclosporin A, researchers found that other immunosuppressants including FK506 and rapamycin could inhibit MDR [191]. However, when cyclosporin A is applied clinically, researchers placed efforts to develop cyclosporin analogues having few side effects due to their innate immuno suppressant effects and hepatic and renal toxicity with excellent chemosensitizing effects. As a result, PSC-833 (Valspodar), which is the non-immune suppressant analogue of cyclosporin, was developed [110]. In addition to non-immunosuppressant effect, its chemosensitivity is about 10 times higher than that by cyclosporin in Pgp-mediated MDR, so clinical studies are being performed on this drug [192]. Among those drugs having their innate pharmacological activities such as verapamil and cyclosporin A, those having chemosensitizing effect is called the first-generation chemosensitizers. The problems related with the first-generation chemosensitizers are that they generally show low effects and high toxicity at resistance-inhibiting doses. In order to supplement these problems, the chemosensitizers developed only for chemosensitizing effects are called the second-generation chemosensitizers, which include PSC-833, VX-710, LY335979, XR9051 and XR9576 [193]. Multi-national companies are pursuing the development of second-generation chemosensitizers by overcoming the problems of existing chemosensitizers (low effects, side effects, and drug-drug interaction), and some of these chemosensitizers are in the process of being tested clinically.

Most chemosensitizers bind with TMD in transporter, but steroid and flavonoid are new recently introduced chemosensitizers, which inhibit transporters by binding with NBD. The binding site of steroid is different from the binding site of ATP but is probably in the vicinity of the ATP binding site [194]. On the other hand, the flavonoid, kaempferide, is bifunctional in that it would partially block the binding of the antiprogestin RU-486 in the cytoplasm domain of Pgp and block ATP binding [195] (Fig. 4). Recently, flavonoid chemosensitizers reversing Pgp-mediated MDR have been screening. It is believed that flavonoid chemosensitizers have a significant advantage with respect with a therapeutic index (Table 4). These may be second-generation flavonoid chemosensitizers [33].
Figure 4

Proposed schematic model of NBDs showing the relative positions of different nucleotide- and effector-binding sites. MANT-ATP binding is prevented by preincubation with antiprogestin RU-486 and bound MANT-ATP is displaced by Ru-486, suggesting the existence of a cytosolic steroidal-interacting region adjacent to the ATP-binding site. Since the flavonoid binding is prevented by preincubation with ATP and RU-486, bound flavonoids most likely cover both ATP site and the vicinal steroid site. MANT, 2'(3')-N-methylanthraniloyl [3].

Table 3

Chemosensitizers inhibiting Pgp, MRP and BCRP

Name

Year

Chemosensitizer

Pgp

2004

Benzyl-, phenethyl-, and alpha-naphthyl isothiocyanates [16], diallyl sulfide [17], PK11195 [18], small scFv recombinant Pgp antibody fragment [19]

2003

Amooranin [20], etrandrine, fangchinoline [21], ginsenoside Rg(3) [22], KR30031 [23], methylenedioxyethylamphetamine [24], protopanaxatriol ginsenosides [25], saquinavir [26], siRNA of mdr1 gene [27, 28], tRA 98006* [29]

2002

3,5-dibenzoyl-1,4-dihydropyridines[30], PKC412 [31], pyronaridine [32], sinensetin [33]

2001

Agosterol A [34], haloperidol and dihydrohaloperidol [35], SB203580 [36], tropane alkaloid esters [37], SNF4435C and D [38], tea polyphenol [39], trans-N,N'-bis(3,4-dimethoxybenzyl)-N-solanesyl-1,2-diaminocyclo hexane (N-5228) [40]

2000

Astemizole [41], atorvastatin [42], 7-O-benzoylpyripyropene A [43], 5-O-benzoylated taxinine k [44], clarithromycin and YM17K (3,4'-dideoxy mycaminosyl tylonolide hydrochloride) [45], cyclopamine and tomatidine[46], 3,5-diacetyl-1,4-dihydropyridines [47], 7, 8-dihydroxy-3-benzazepine [48], doxorubicin-gallium-transferrin conjugate [49], macrolide antibiotics (josamycin, tamolarizine) [50], nelfinavir [51] norverapamil [52], ontogen (ONT-093, formerly OC-144-093) [53], R101933 [54], taxuspine C, 2'-desacetoxyaustrospicatine and 2-desacetoxytaxinine [55], V-104 [56]

1999

D-alpha-tocopheryl polyethylene glycol 1000 succinate [57], anti-MDR1 ribozymes [58], AR-2 [59], carvedilol [60], erythromycin [61], ketoconazole [62], kopsiflorine [63], nomegestrol [64], PAK-200S [65], pluronic block copolymer [66], reversin [67], ritonarvir [68], rosemary extract [69], TTD [70], XR9576(2) [71]

1998

Ardeemins [72], AV200 [73], 5-O-benzoylated taxuspine C [74], bromocriptine [75], dipyridamole [76], droloxifene [77], imidazothiazole derivatives (N276-12, N276-14, N276-17) [78], oxalyl bis(N-phenyl)hydroxamic acid [79], tetrandine and fangchinoline [21], tiamulin [80], XR9051 [81]

1997

Biricodar (VX-710; Incel) [82, 83], cyproheptadine [84]

1996

CL 329,753 [85], indole-3-carbinol [86], itraconazole [87], LY335979 [88], medroxyprogesterone [89], mefloquine [90], mifepristone (RU-486) [91], reserpine [92]

1995

Azelastine and flezelastine [93], B9209-005 [94], dexniguldipine (B8509-035) [95], dexverapamil [96], epidermal growth factor (EGF), insulin-like growth factor I (IGF-I) [97], quercetin [98]

1994

MS-209 [99], pentoxifylline [100], Ro11-2933 (DMDP) [101], RU486 [102]

1993

Dilantin [103], GF120918[104], meperidine, pentazocine, and methadone [105], Pgp monoclonal antibodies and antisense oligonucleotide [106], tamoxifen and toremifene [107]

1992

Staurosporine and NA-382 [108]

1991

Biperidil [109], SDZ PSC 833[110]

1990

Cremophor EL [111]

1989

Cefoperazone, cetriaxone [112], phenothiazine [113], YM534 [114]

1987

Diltiazem[115], cyclosporine A [116]

1986

Aamiodarone [117]

1984

Quinidine [118]

1981

Verapamil [119],

MRP

2004

benzyl-, phenethyl-, and alpha-naphthyl isothiocyanates [16]

2003

tRA 98006 [29]

2001

Agosterol A [34]

2000

5-O-benzoylated taxinine k [44], 4-deacetoxyagosterol A [120], doxorubicin-gallium-transferrin conjugate [49], V-104 [56], pluronic block copolymer [66], quinoline-based drugs (chloroquine, quinine, quinidine, and primaquine) [121],

1999

dipyridamole [122], erythromycin and ofloxacin [123], mifepristone (RU-486) [124], MS-209 [125], rifampicin [126]

1998

Biricodar (VX-710; Incel) [83], imidazothiazole derivatives (N276-12, N276-14, N276-17) [78], NSAIDs (indomethacin, sulindac, tolmetin, acemetacin, zomepirac and mefenamic acid) [127], ONO-1078 [128], quercetin [98]

1997

Indomethacin [129], probenecid [130]

1996

Acrolein and chloroacetaldehyde [131], d,l-buthionine-(S,R)-sulfoximine [132], itraconazol [87], PAK-104P [133]

1995

Difloxacin [134], MK571 [135]

BCRP

2004

Chrysin and biochanin A [136], genistein and naligenin [137], Imatinib mesylate (Gleevec, STI571) [138]

2003

Estrone, diethylstilbestrol and TAG-139 [139], tRA 98006 [29]

2002

Ko143 [140]

1999

GF120918 [141]

1998

fumitremorgin C [142]

* Boldface compounds indicate chemosensitizers inhibiting more than two transporters

Table 4

Comparison of chemosensitizing effects of flavonoids and verapamil against Pgp

Chemosensitizer

IC50a(μM)

CIc

(VCRb-)

(VCR+)

5,7,3',4',5' – pentamethoxyflavone

> 400

0.4

>1000

7,3',4' – trimethoxyflavone

> 400

1.2

>333.3

3',4' – dimethoxyflavone

386

1.2

321.7

3,6,3',4' – tetramethoxyflavone

> 400

1.9

>210.5

Verapamil

61

0.4

152.5

5,6,7,3',4' – pentamethoxyflavone

> 400

3.2

>125

Cytotoxic and chemosensitizing effects of chemosensitizers in the presence or absence of vincristine in Pgp-overexpressing AML-2/D100 cells.

a, Drug concentrations with inhibit 50% growth of the cells.

b, Vincristine (100 ng/ml)

c, Chemosensitizing index = IC50 (VCR-)/IC50(VCR+)

The fungal toxin, fumitremorgin C (FTC), is a strong inhibitor of BCRP but its use in vivo has been limited due to its neurotoxicity [196]. It was recently reported that the tetracyclic analogue of FTC, Ko143, is the most strong chemosensitizer aginst BCRP having little toxicity [140].

Since ABC transporters can be coexpressed in some types of cancer cells, the development of chemosensitizers against MRP and/or BCRP as well as Pgp has been highly demanding. These include VX-710 against Pgp and MRP [82, 83], GF120918 against Pgp and BCRP [104, 141] and tRA98006 against all three transporters [29].

Conclusion

One of the major causes of failure in anticancer chemotherapy is resistance against anticancer drugs. Overexpression of ABC transporters such as Pgp, MRP and BCRP has been shown to be responsible for the major portion of MDR. Therefore elucidation of the structure and the function for each ABC transporter is prerequisite for understanding how these transporters work and for reversing MDR. One strategy for reversal of MDR cells expressing ABC transporters is combined use of anticancer drugs with chemosensitizers. Second-generation chemosensitizers have been developed for the purpose of obtaining higher efficacy and lower toxicity than first-generation chemosensitizers. Inhibitors of ABC transporters can be exploited to enhance the oral bioavailablilty or the brain penetration of various drugs.

Combination of a conventional anticancer chemotherapy with new strategies such as chemosensitizers, receptor-mediated targeting and nanotechnology will shed light on cancer patients in the near future.

Declarations

Acknowledgements

This study was supported by grants from Ministry of Science and Technology, Korea, and from Korea Science and Engineering Foundation through Research Center for Resistant Cells (R13-2003-009). I gratefully thank Dr. Bum-Chae Choi of the CL hospital located in Gwangju (Korea) for critical reading of the manuscript.

Authors’ Affiliations

(1)
Research Center for Resistant Cells, Chosun University Medical School

References

  1. Stavrovskaya AA: Cellular mechanisms of multidrug resistance of tumor cells. Biochemistry (Mosc). 2000, 65: 95-106.Google Scholar
  2. Riordan JR, Ling V: Purification of P-glycoprotein from plasma membrane vesicles of Chinese hamster ovary cell mutants with reduced colchicine permeability. J Biol Chem. 1979, 254: 12701-12705.PubMedGoogle Scholar
  3. Di Pietro A, Dayan G, Conseil G, Steinfels E, Krell T, Trompier D, Baubichon-Cortay H, Jault J: P-glycoprotein-mediated resistance to chemotherapy in cancer cells: using recombinant cytosolic domains to establish structure-function relationships. Braz J Med Biol Res. 1999, 32: 925-939. 10.1590/S0100-879X1999000800001.PubMedGoogle Scholar
  4. Dean M, Hamon Y, Chimini G: The human ATP-binding cassette (ABC) transporter superfamily. J Lipid Res. 2001, 42: 1007-1017.PubMedGoogle Scholar
  5. Efferth T: The human ATP-binding cassette transporter genes: from the bench to the bedside. Curr Mol Med. 2001, 1: 45-65. 10.2174/1566524013364194.PubMedGoogle Scholar
  6. Cole SP, Bhardwaj G, Gerlach JH, Mackie JE, Grant CE, Almquist KC, Stewart AJ, Kurz EU, Duncan AM, Deeley RG: Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science. 1992, 258: 1650-1654.PubMedGoogle Scholar
  7. Doyle LA, Yang W, Abruzzo LV, Krogmann T, Gao Y, Rishi AK, Ross DD: A multidrug resistance transporter from human MCF-7 breast cancer cells. Proc Natl Acad Sci U S A. 1998, 95: 15665-15670. 10.1073/pnas.95.26.15665.PubMed CentralPubMedGoogle Scholar
  8. Maliepaard M, van Gastelen MA, de Jong LA, Pluim D, van Waardenburg RC, Ruevekamp-Helmers MC, Floot BG, Schellens JH: Overexpression of the BCRP/MXR/ABCP gene in a topotecan-selected ovarian tumor cell line. Cancer Res. 1999, 59: 4559-4563.PubMedGoogle Scholar
  9. Bell DR, Trent JM, Willard HF, Riordan JR, Ling V: Chromosomal location of human P-glycoprotein gene sequences. Cancer Genet Cytogenet. 1987, 25: 141-148. 10.1016/0165-4608(87)90169-5.PubMedGoogle Scholar
  10. van Kuijck MA, Kool M, Merkx GF, Geurts van Kessel A, Bindels RJ, Deen PM, van Os CH: Assignment of the canalicular multispecific organic anion transporter gene (CMOAT) to human chromosome 10q24 and mouse chromosome 19D2 by fluorescent in situ hybridization. Cytogenet Cell Genet. 1997, 77: 285-287.PubMedGoogle Scholar
  11. Kool M, de Haas M, Scheffer GL, Scheper RJ, van Eijk MJ, Juijn JA, Baas F, Borst P: Analysis of expression of cMOAT (MRP2), MRP3, MRP4, and MRP5, homologues of the multidrug resistance-associated protein gene (MRP1), in human cancer cell lines. Cancer Res. 1997, 57: 3537-3547.PubMedGoogle Scholar
  12. Kool M, van der Linden M, de Haas M, Baas F, Borst P: Expression of human MRP6, a homologue of the multidrug resistance protein gene MRP1, in tissues and cancer cells. Cancer Res. 1999, 59: 175-182.PubMedGoogle Scholar
  13. Hopper E, Belinsky MG, Zeng H, Tosolini A, Testa JR, Kruh GD: Analysis of the structure and expression pattern of MRP7 (ABCC10), a new member of the MRP subfamily. Cancer Lett. 2001, 162: 181-191. 10.1016/S0304-3835(00)00646-7.PubMedGoogle Scholar
  14. Bera TK, Lee S, Salvatore G, Lee B, Pastan I: MRP8, a new member of ABC transporter superfamily, identified by EST database mining and gene prediction program, is highly expressed in breast cancer. Mol Med. 2001, 7: 509-516.PubMed CentralPubMedGoogle Scholar
  15. Knutsen T, Rao VK, Ried T, Mickley L, Schneider E, Miyake K, Ghadimi BM, Padilla-Nash H, Pack S, Greenberger L, Cowan K, Dean M, Fojo T, Bates S: Amplification of 4q21-q22 and the MXR gene in independently derived mitoxantrone-resistant cell lines. Genes Chromosomes Cancer. 2000, 27: 110-116. 10.1002/(SICI)1098-2264(200001)27:1<110::AID-GCC14>3.0.CO;2-4.PubMedGoogle Scholar
  16. Hu K, Morris ME: Effects of benzyl-, phenethyl-, and alpha-naphthyl isothiocyanates on P-glycoprotein- and MRP1-mediated transport. J Pharm Sci. 2004, 93: 1901-1911. 10.1002/jps.20101.PubMedGoogle Scholar
  17. Arora A, Seth K, Shukla Y: Reversal of P-glycoprotein-mediated multidrug resistance by diallyl sulfide in K562 leukemic cells and in mouse liver. Carcinogenesis. 2004, 25: 941-949. 10.1093/carcin/bgh060.PubMedGoogle Scholar
  18. Walter RB, Raden BW, Cronk MR, Bernstein ID, Appelbaum FR, Banker DE: The peripheral benzodiazepine receptor ligand PK11195 overcomes different resistance mechanisms to sensitize AML cells to gemtuzumab ozogamicin. Blood. 2004, 103: 4276-4284. 10.1182/blood-2003-11-3825.PubMedGoogle Scholar
  19. Haus-Cohen M, Assaraf YG, Binyamin L, Benhar I, Reiter Y: Disruption of P-glycoprotein anticancer drug efflux activity by a small recombinant single-chain Fv antibody fragment targeted to an extracellular epitope. Int J Cancer. 2004, 109: 750-758. 10.1002/ijc.20037.PubMedGoogle Scholar
  20. Ramachandran C, Rabi T, Fonseca HB, Melnick SJ, Escalon EA: Novel plant triterpenoid drug amooranin overcomes multidrug resistance in human leukemia and colon carcinoma cell lines. Int J Cancer. 2003, 105: 784-789. 10.1002/ijc.11180.PubMedGoogle Scholar
  21. Choi SU, Park SH, Kim KH, Choi EJ, Kim S, Park WK, Zhang YH, Kim HS, Jung NP, Lee CO: The bisbenzylisoquinoline alkaloids, tetrandine and fangchinoline, enhance the cytotoxicity of multidrug resistance-related drugs via modulation of P-glycoprotein. Anticancer Drugs. 1998, 9: 255-261.PubMedGoogle Scholar
  22. Kim SW, Kwon HY, Chi DW, Shim JH, Park JD, Lee YH, Pyo S, Rhee DK: Reversal of P-glycoprotein-mediated multidrug resistance by ginsenoside Rg(3). Biochem Pharmacol. 2003, 65: 75-82. 10.1016/S0006-2952(02)01446-6.PubMedGoogle Scholar
  23. Lee BH, Lee CO, Kwon MJ, Yi KY, Yoo SE, Choi SU: Differential effects of the optical isomers of KR30031 on cardiotoxicity and on multidrug resistance reversal activity. Anticancer Drugs. 2003, 14: 175-181. 10.1097/00001813-200302000-00012.PubMedGoogle Scholar
  24. Ketabi-Kiyanvash N, Weiss J, Haefeli WE, Mikus G: P-glycoprotein modulation by the designer drugs methylenedioxymethamphetamine, methylenedioxyethylamphetamine and paramethoxyamphetamine. Addict Biol. 2003, 8: 413-418. 10.1080/13556210310001646475.PubMedGoogle Scholar
  25. Choi CH, Kang G, Min YD: Reversal of P-glycoprotein-mediated multidrug resistance by protopanaxatriol ginsenosides from Korean red ginseng. Planta Med. 2003, 69: 235-240. 10.1055/s-2003-38483.PubMedGoogle Scholar
  26. Dupuis ML, Tombesi M, Sabatini M, Cianfriglia M: Differential effect of HIV-1 protease inhibitors on P-glycoprotein function in multidrug-resistant variants of the human CD4+ T lymphoblastoid CEM cell line. Chemotherapy. 2003, 49: 8-16. 10.1159/000069782.PubMedGoogle Scholar
  27. Nieth C, Priebsch A, Stege A, Lage H: Modulation of the classical multidrug resistance (MDR) phenotype by RNA interference (RNAi). FEBS Lett. 2003, 545: 144-150. 10.1016/S0014-5793(03)00523-4.PubMedGoogle Scholar
  28. Wu H, Hait WN, Yang JM: Small interfering RNA-induced suppression of MDR1 (P-glycoprotein) restores sensitivity to multidrug-resistant cancer cells. Cancer Res. 2003, 63: 1515-1519.PubMedGoogle Scholar
  29. Brooks T, Minderman H, O'Loughlin KL, Pera P, Ojima I, Baer MR, Bernacki RJ: Taxane-based reversal agents modulate drug resistance mediated by P-glycoprotein, multidrug resistance protein, and breast cancer resistance protein. Mol Cancer Ther. 2003, 2: 1195-1205.PubMedGoogle Scholar
  30. Kawase M, Shah A, Gaveriya H, Motohashi N, Sakagami H, Varga A, Molnar J: 3,5-dibenzoyl-1,4-dihydropyridines: synthesis and MDR reversal in tumor cells. Bioorg Med Chem. 2002, 10: 1051-1055. 10.1016/S0968-0896(01)00363-7.PubMedGoogle Scholar
  31. Ganeshaguru K, Wickremasinghe RG, Jones DT, Gordon M, Hart SM, Virchis AE, Prentice HG, Hoffbrand AV, Man A, Champain K, Csermak K, Mehta AB: Actions of the selective protein kinase C inhibitor PKC412 on B-chronic lymphocytic leukemia cells in vitro. Haematologica. 2002, 87: 167-176.PubMedGoogle Scholar
  32. Qi J, Yang CZ, Wang CY, Wang SB, Yang M, Wang JH: Function and mechanism of pyronaridine: a new inhibitor of P-glycoprotein-mediated multidrug resistance. Acta Pharmacol Sin. 2002, 23: 544-550.PubMedGoogle Scholar
  33. Choi CH, Sun KH, An CS, Yoo JC, Hahm KS, Lee IH, Sohng JK, Kim YC: Reversal of P-glycoprotein-mediated multidrug resistance by 5,6,7,3',4'-pentamethoxyflavone (Sinensetin). Biochem Biophys Res Commun. 2002, 295: 832-840. 10.1016/S0006-291X(02)00755-6.PubMedGoogle Scholar
  34. Murakami N, Sugimoto M, Morita M, Kobayashi M: Total synthesis of agosterol A: an MDR-modulator from a marine sponge. Chemistry. 2001, 7: 2663-2670. 10.1002/1521-3765(20010618)7:12<2663::AID-CHEM26630>3.0.CO;2-U.PubMedGoogle Scholar
  35. Kataoka Y, Ishikawa M, Miura M, Takeshita M, Fujita R, Furusawa S, Takayanagi M, Takayanagi Y, Sasaki K: Reversal of vinblastine resistance in human leukemic cells by haloperidol and dihydrohaloperidol. Biol Pharm Bull. 2001, 24: 612-617. 10.1248/bpb.24.612.PubMedGoogle Scholar
  36. Barancik M, Bohacova V, Kvackajova J, Hudecova S, Krizanova O, Breier A: SB203580, a specific inhibitor of p38-MAPK pathway, is a new reversal agent of P-glycoprotein-mediated multidrug resistance. Eur J Pharm Sci. 2001, 14: 29-36. 10.1016/S0928-0987(01)00139-7.PubMedGoogle Scholar
  37. Silva GL, Cui B, Chavez D, You M, Chai HB, Rasoanaivo P, Lynn SM, O'Neill MJ, Lewis JA, Besterman JM, Monks A, Farnsworth NR, Cordell GA, Pezzuto JM, Kinghorn AD: Modulation of the multidrug-resistance phenotype by new tropane alkaloid aromatic esters from Erythroxylum pervillei. J Nat Prod. 2001, 64: 1514-1520. 10.1021/np010295+.PubMedGoogle Scholar
  38. Kurosawa K, Takahashi K, Tsuda E, Tomida A, Tsuruo T: Reversal of multidrug resistance by novel nitrophenyl pyrones, SNF4435C and D. Jpn J Cancer Res. 2001, 92: 1235-1241.PubMedGoogle Scholar
  39. Zhu A, Wang X, Guo Z: Study of tea polyphenol as a reversal agent for carcinoma cell lines' multidrug resistance (study of TP as a MDR reversal agent). Nucl Med Biol. 2001, 28: 735-740. 10.1016/S0969-8051(00)90202-6.PubMedGoogle Scholar
  40. Hayashi M, Koike K, Rho MC, Kuwano M, Kishiye T, Komiyama K: Reversal of P-glycoprotein associated multidrug resistance by new isoprenoid derivatives. Anticancer Drug Des. 2001, 16: 255-260.PubMedGoogle Scholar
  41. Ishikawa M, Fujita R, Takayanagi M, Takayanagi Y, Sasaki K: Reversal of acquired resistance to doxorubicin in K562 human leukemia cells by astemizole. Biol Pharm Bull. 2000, 23: 112-115.PubMedGoogle Scholar
  42. Boyd RA, Stern RH, Stewart BH, Wu X, Reyner EL, Zegarac EA, Randinitis EJ, Whitfield L: Atorvastatin coadministration may increase digoxin concentrations by inhibition of intestinal P-glycoprotein-mediated secretion. J Clin Pharmacol. 2000, 40: 91-98. 10.1177/00912700022008612.PubMedGoogle Scholar
  43. Rho MC, Hayashi M, Fukami A, Obata R, Sunazuka T, Tomoda H, Komiyama K, Omura S: Reversal of multidrug resistance by 7-O-benzoylpyripyropene A in multidrug-resistant tumor cells. J Antibiot (Tokyo). 2000, 53: 1201-1206.Google Scholar
  44. Okumura H, Chen ZS, Sakou M, Sumizawa T, Furukawa T, Komatsu M, Ikeda R, Suzuki H, Hirota K, Aikou T, Akiyama SI: Reversal of P-glycoprotein and multidrug-resistance protein-mediated drug resistance in KB cells by 5-O-benzoylated taxinine K. Mol Pharmacol. 2000, 58: 1563-1569.PubMedGoogle Scholar
  45. Wang L, Kitaichi K, Hui CS, Takagi K, Sakai M, Yokogawa K, Miyamoto KI, Hasegawa T: Reversal of anticancer drug resistance by macrolide antibiotics in vitro and in vivo. Clin Exp Pharmacol Physiol. 2000, 27: 587-593. 10.1046/j.1440-1681.2000.03308.x.PubMedGoogle Scholar
  46. Lavie Y, Harel-Orbital T, Gaffield W, Liscovitch M: Inhibitory effect of steroidal alkaloids on drug transport and multidrug resistance in human cancer cells. Anticancer Res. 2001, 21: 1189-1194.PubMedGoogle Scholar
  47. Shah A, Gaveriya H, Motohashi N, Kawase M, Saito S, Sakagami H, Satoh K, Tada Y, Solymosi A, Walfard K, Molnar J: 3,5-diacetyl-1,4-dihydropyridines: synthesis and MDR reversal in tumor cells. Anticancer Res. 2000, 20: 373-377.PubMedGoogle Scholar
  48. Kawase M, Saito S, Motohashi N: Chemistry and biological activity of new 3-benzazepines. Int J Antimicrob Agents. 2000, 14: 193-201. 10.1016/S0924-8579(99)00155-7.PubMedGoogle Scholar
  49. Wang F, Jiang X, Yang DC, Elliott RL, Head JF: Doxorubicin-gallium-transferrin conjugate overcomes multidrug resistance: evidence for drug accumulation in the nucleus of drug resistant MCF-7/ADR cells. Anticancer Res. 2000, 20: 799-808.PubMedGoogle Scholar
  50. Miyake N, Fujita R, Ishikawa M, Takayanagi M, Takayanagi Y, Sasaki K: Reversal of multidrug resistance in human leukemia K562 by tamolarizine, a novel calcium antagonist. Jpn J Pharmacol. 2000, 82: 265-268. 10.1254/jjp.82.265.PubMedGoogle Scholar
  51. Shiraki N, Hamada A, Yasuda K, Fujii J, Arimori K, Nakano M: Inhibitory effect of human immunodeficiency virus protease inhibitors on multidrug resistance transporter P-glycoproteins. Biol Pharm Bull. 2000, 23: 1528-1531.PubMedGoogle Scholar
  52. Pauli-Magnus C, von Richter O, Burk O, Ziegler A, Mettang T, Eichelbaum M, Fromm MF: Characterization of the major metabolites of verapamil as substrates and inhibitors of P-glycoprotein. J Pharmacol Exp Ther. 2000, 293: 376-382.PubMedGoogle Scholar
  53. Newman MJ, Rodarte JC, Benbatoul KD, Romano SJ, Zhang C, Krane S, Moran EJ, Uyeda RT, Dixon R, Guns ES, Mayer LD: Discovery and characterization of OC144-093, a novel inhibitor of P-glycoprotein-mediated multidrug resistance. Cancer Res. 2000, 60: 2964-2972.PubMedGoogle Scholar
  54. van Zuylen L, Sparreboom A, van der Gaast A, van der Burg ME, van Beurden V, Bol CJ, Woestenborghs R, Palmer PA, Verweij J: The orally administered P-glycoprotein inhibitor R101933 does not alter the plasma pharmacokinetics of docetaxel. Clin Cancer Res. 2000, 6: 1365-1371.PubMedGoogle Scholar
  55. Kobayashi J, Shigemori H, Hosoyama H, Chen Z, Akiyama S, Naito M, Tsuruo T: Multidrug resistance reversal activity of taxoids from Taxus cuspidata in KB-C2 and 2780AD cells. Jpn J Cancer Res. 2000, 91: 638-642.PubMedGoogle Scholar
  56. Evers R, Kool M, Smith AJ, van Deemter L, de Haas M, Borst P: Inhibitory effect of the reversal agents V-104, GF120918 and Pluronic L61 on MDR1 Pgp-, MRP1- and MRP2-mediated transport. Br J Cancer. 2000, 83: 366-374. 10.1054/bjoc.2000.1260.PubMed CentralPubMedGoogle Scholar
  57. Dintaman JM, Silverman JA: Inhibition of P-glycoprotein by D-alpha-tocopheryl polyethylene glycol 1000 succinate (TPGS). Pharm Res. 1999, 16: 1550-1556. 10.1023/A:1015000503629.PubMedGoogle Scholar
  58. Wang FS, Kobayashi H, Liang KW, Holland JF, Ohnuma T: Retrovirus-mediated transfer of anti-MDR1 ribozymes fully restores chemosensitivity of P-glycoprotein-expressing human lymphoma cells. Hum Gene Ther. 1999, 10: 1185-1195. 10.1089/10430349950018175.PubMedGoogle Scholar
  59. Alexanian AR, Arutyunian NS: Reversal of drug resistance in sarcoma-45 by the new calmodulin antagonist--trihydrochloride of [1,2,5-trimethyl-4-phenyl-4-beta-[N-(beta-ethylamino)-N-4'-methoxybe nzy l]-ethylamino] piperidine (AR-2). Invest New Drugs. 1999, 17: 105-110. 10.1023/A:1006397014409.PubMedGoogle Scholar
  60. Jonsson O, Behnam-Motlagh P, Persson M, Henriksson R, Grankvist K: Increase in doxorubicin cytotoxicity by carvedilol inhibition of P-glycoprotein activity. Biochem Pharmacol. 1999, 58: 1801-1806. 10.1016/S0006-2952(99)00262-2.PubMedGoogle Scholar
  61. Siedlik PH, Olson SC, Yang BB, Stern RH: Erythromycin coadministration increases plasma atorvastatin concentrations. J Clin Pharmacol. 1999, 39: 501-504.PubMedGoogle Scholar
  62. Kim RB, Wandel C, Leake B, Cvetkovic M, Fromm MF, Dempsey PJ, Roden MM, Belas F, Chaudhary AK, Roden DM, Wood AJ, Wilkinson GR: Interrelationship between substrates and inhibitors of human CYP3A and P-glycoprotein. Pharm Res. 1999, 16: 408-414. 10.1023/A:1018877803319.PubMedGoogle Scholar
  63. Rho MC, Toyoshima M, Hayashi M, Koyano T, Subramaniam G, Kam TS, Komiyama K: Reversal of multidrug resistance by kopsiflorine isolated from Kopsia dasyrachis. Planta Med. 1999, 65: 307-310. 10.1055/s-1999-13991.PubMedGoogle Scholar
  64. Li J, Xu L, He K: [Modulation of multiple drug resistance by nomegestrol acetate and droloxifene in K562/A02]. Zhonghua Xue Ye Xue Za Zhi. 1999, 20: 288-291.PubMedGoogle Scholar
  65. Vanhoefer U, Muller MR, Hilger RA, Lindtner B, Klaassen U, Schleucher N, Rustum YM, Seeber S, Harstrick A: Reversal of MDR1-associated resistance to topotecan by PAK-200S, a new dihydropyridine analogue, in human cancer cell lines. Br J Cancer. 1999, 81: 1304-1310. 10.1038/sj.bjc.6694384.PubMed CentralPubMedGoogle Scholar
  66. Miller DW, Batrakova EV, Kabanov AV: Inhibition of multidrug resistance-associated protein (MRP) functional activity with pluronic block copolymers. Pharm Res. 1999, 16: 396-401. 10.1023/A:1018873702411.PubMedGoogle Scholar
  67. Sharom FJ, Yu X, Lu P, Liu R, Chu JW, Szabo K, Muller M, Hose CD, Monks A, Varadi A, Seprodi J, Sarkadi B: Interaction of the P-glycoprotein multidrug transporter (MDR1) with high affinity peptide chemosensitizers in isolated membranes, reconstituted systems, and intact cells. Biochem Pharmacol. 1999, 58: 571-586. 10.1016/S0006-2952(99)00139-2.PubMedGoogle Scholar
  68. Drewe J, Gutmann H, Fricker G, Torok M, Beglinger C, Huwyler J: HIV protease inhibitor ritonavir: a more potent inhibitor of P-glycoprotein than the cyclosporine analog SDZ PSC 833. Biochem Pharmacol. 1999, 57: 1147-1152. 10.1016/S0006-2952(99)00026-X.PubMedGoogle Scholar
  69. Plouzek CA, Ciolino HP, Clarke R, Yeh GC: Inhibition of P-glycoprotein activity and reversal of multidrug resistance in vitro by rosemary extract. Eur J Cancer. 1999, 35: 1541-1545. 10.1016/S0959-8049(99)00180-X.PubMedGoogle Scholar
  70. Xu JY, Zhou Q, Shen P, Tang W: Reversal effect of TTD on human multidrug resistant KBV200 cell line. J Exp Clin Cancer Res. 1999, 18: 549-552.PubMedGoogle Scholar
  71. Roe M, Folkes A, Ashworth P, Brumwell J, Chima L, Hunjan S, Pretswell I, Dangerfield W, Ryder H, Charlton P: Reversal of P-glycoprotein mediated multidrug resistance by novel anthranilamide derivatives. Bioorg Med Chem Lett. 1999, 9: 595-600. 10.1016/S0960-894X(99)00030-X.PubMedGoogle Scholar
  72. Chou TC, Depew KM, Zheng YH, Safer ML, Chan D, Helfrich B, Zatorska D, Zatorski A, Bornmann W, Danishefsky SJ: Reversal of anticancer multidrug resistance by the ardeemins. Proc Natl Acad Sci U S A. 1998, 95: 8369-8374. 10.1073/pnas.95.14.8369.PubMed CentralPubMedGoogle Scholar
  73. Mendez-Vidal C, Quesada AR: Reversal of P-glycoprotein-mediated multidrug resistance in vitro by AV200, a new ardeemin derivative. Cancer Lett. 1998, 132: 45-50. 10.1016/S0304-3835(98)00156-6.PubMedGoogle Scholar
  74. Sako M, Suzuki H, Hirota K: Syntheses of taxuspine C derivatives as functional inhibitors of P-glycoprotein, an ATP-associated cell-membrane transporter. Chem Pharm Bull (Tokyo). 1998, 46: 1135-1139.Google Scholar
  75. Orlowski S, Valente D, Garrigos M, Ezan E: Bromocriptine modulates P-glycoprotein function. Biochem Biophys Res Commun. 1998, 244: 481-488. 10.1006/bbrc.1998.8289.PubMedGoogle Scholar
  76. Hosoi E, Hirose M, Hamano S, Morimoto M, Kuroda Y: Effect of MDR antagonists on the cidal activity of vincristine for cells expressing MDR-1 is superior to those expressing MRP. Int J Oncol. 1998, 13: 343-348.PubMedGoogle Scholar
  77. Nussler V, Pelka-Fleisc R, Gieseler F, Hasmann M, Loser R, Gullis E, Stotzer O, Zwierzina H, Wilmanns W: In vitro efficacy of known P-glycoprotein modulators compared to droloxifene E and Z: studies on a human T-cell leukemia cell line and their resistant variants. Leuk Lymphoma. 1998, 31: 589-597.PubMedGoogle Scholar
  78. Naito S, Koike K, Ono M, Machida T, Tasaka S, Kiue A, Koga H, Kumazawa J: Development of novel reversal agents, imidazothiazole derivatives, targeting MDR1- and MRP-mediated multidrug resistance. Oncol Res. 1998, 10: 123-132.PubMedGoogle Scholar
  79. Choudhuri SK, Chatterjee A: Reversal of resistance against doxorubicin by a newly developed compound, oxalyl bis(N-phenyl)hydroxamic acid in vitro. Anticancer Drugs. 1998, 9: 825-832.PubMedGoogle Scholar
  80. Baggetto LG, Dong M, Bernaud J, Espinosa L, Rigal D, Bonvallet R, Marthinet E: In vitro and in vivo reversal of cancer cell multidrug resistance by the semi-synthetic antibiotic tiamulin. Biochem Pharmacol. 1998, 56: 1219-1228. 10.1016/S0006-2952(98)00229-9.PubMedGoogle Scholar
  81. Dale IL, Tuffley W, Callaghan R, Holmes JA, Martin K, Luscombe M, Mistry P, Ryder H, Stewart AJ, Charlton P, Twentyman PR, Bevan P: Reversal of P-glycoprotein-mediated multidrug resistance by XR9051, a novel diketopiperazine derivative. Br J Cancer. 1998, 78: 885-892.PubMed CentralPubMedGoogle Scholar
  82. Germann UA, Shlyakhter D, Mason VS, Zelle RE, Duffy JP, Galullo V, Armistead DM, Saunders JO, Boger J, Harding MW: Cellular and biochemical characterization of VX-710 as a chemosensitizer: reversal of P-glycoprotein-mediated multidrug resistance in vitro. Anticancer Drugs. 1997, 8: 125-140.PubMedGoogle Scholar
  83. Rowinsky EK, Smith L, Wang YM, Chaturvedi P, Villalona M, Campbell E, Aylesworth C, Eckhardt SG, Hammond L, Kraynak M, Drengler R, Stephenson J, Harding MW, Von Hoff DD: Phase I and pharmacokinetic study of paclitaxel in combination with biricodar, a novel agent that reverses multidrug resistance conferred by overexpression of both MDR1 and MRP. J Clin Oncol. 1998, 16: 2964-2976.PubMedGoogle Scholar
  84. Miao ZH, Li XT, Zhu YJ: [Reversal of multidrug resistance by cyproheptadine in KBV200 cells]. Yao Xue Xue Bao. 1997, 32: 321-325.PubMedGoogle Scholar
  85. Greenberger LM, Collins KI, Annable T, Boni JP, May MK, Lai FM, Kramer R, Citeralla RV, Hallett WA, Powell D: alpha-(3,4-dimethyoxyphenyl)-3,4-dihydro-6,7-dimethoxy-alpha- [(4-methylphenyl)thio]-2(1H)-isoquinolineheptanenitrile (CL 329,753): a novel chemosensitizing agent for P-glycoprotein-mediated resistance with improved biological properties compared with verapamil and cyclosporine A. Oncol Res. 1996, 8: 207-218.PubMedGoogle Scholar
  86. Christensen JG, LeBlanc GA: Reversal of multidrug resistance in vivo by dietary administration of the phytochemical indole-3-carbinol. Cancer Res. 1996, 56: 574-581.PubMedGoogle Scholar
  87. Kurosawa M, Okabe M, Hara N, Kawamura K, Suzuki S, Sakurada K, Asaka M: Reversal effect of itraconazole on adriamycin and etoposide resistance in human leukemia cells. Ann Hematol. 1996, 72: 17-21.PubMedGoogle Scholar
  88. Dantzig AH, Shepard RL, Cao J, Law KL, Ehlhardt WJ, Baughman TM, Bumol TF, Starling JJ: Reversal of P-glycoprotein-mediated multidrug resistance by a potent cyclopropyldibenzosuberane modulator, LY335979. Cancer Res. 1996, 56: 4171-4179.PubMedGoogle Scholar
  89. Claudio JA, Emerman JT: The effects of cyclosporin A, tamoxifen, and medroxyprogesterone acetate on the enhancement of adriamycin cytotoxicity in primary cultures of human breast epithelial cells. Breast Cancer Res Treat. 1996, 41: 111-122. 10.1007/BF01807156.PubMedGoogle Scholar
  90. Riffkin CD, Chung R, Wall DM, Zalcberg JR, Cowman AF, Foley M, Tilley L: Modulation of the function of human MDR1 P-glycoprotein by the antimalarial drug mefloquine. Biochem Pharmacol. 1996, 52: 1545-1552. 10.1016/S0006-2952(96)00556-4.PubMedGoogle Scholar
  91. Fardel O, Courtois A, Drenou B, Lamy T, Lecureur V, le Prise PY, Fauchet R: Inhibition of P-glycoprotein activity in human leukemic cells by mifepristone. Anticancer Drugs. 1996, 7: 671-677.PubMedGoogle Scholar
  92. Schuetz EG, Beck WT, Schuetz JD: Modulators and substrates of P-glycoprotein and cytochrome P4503A coordinately up-regulate these proteins in human colon carcinoma cells. Mol Pharmacol. 1996, 49: 311-318.PubMedGoogle Scholar
  93. Hu YP, Robert J: Azelastine and flezelastine as reversing agents of multidrug resistance: pharmacological and molecular studies. Biochem Pharmacol. 1995, 50: 169-175. 10.1016/0006-2952(95)02055-1.PubMedGoogle Scholar
  94. Borchers C, Ulrich WR, Klemm K, Ise W, Gekeler V, Haas S, Schodl A, Conrad J, Przybylski M, Boer R: B9209-005, an azido derivative of the chemosensitizer dexniguldipine-HCl, photolabels P-glycoprotein. Mol Pharmacol. 1995, 48: 21-29.PubMedGoogle Scholar
  95. Hofmann J, Gekeler V, Ise W, Noller A, Mitterdorfer J, Hofer S, Utz I, Gotwald M, Boer R, Glossmann H: Mechanism of action of dexniguldipine-HCl (B8509-035), a new potent modulator of multidrug resistance. Biochem Pharmacol. 1995, 49: 603-609. 10.1016/0006-2952(94)00479-6.PubMedGoogle Scholar
  96. Thurlimann B, Kroger N, Greiner J, Mross K, Schuller J, Schernhammer E, Schumacher K, Gastl G, Hartlapp J, Kupper H: Dexverapamil to overcome epirubicin resistance in advanced breast cancer. J Cancer Res Clin Oncol. 1995, 121 (Suppl 3): R3-6.PubMedGoogle Scholar
  97. Hirsch-Ernst KI, Ziemann C, Schmitz-Salue C, Foth H, Kahl GF: Modulation of P-glycoprotein and mdr1b mRNA expression by growth factors in primary rat hepatocyte culture. Biochem Biophys Res Commun. 1995, 215: 179-185. 10.1006/bbrc.1995.2450.PubMedGoogle Scholar
  98. Kim SH, Yeo GS, Lim YS, Kang CD, Kim CM, Chung BS: Suppression of multidrug resistance via inhibition of heat shock factor by quercetin in MDR cells. Exp Mol Med. 1998, 30: 87-92.PubMedGoogle Scholar
  99. Tsuruo T: [MDR reversing drugs for clinical development]. Gan To Kagaku Ryoho. 1994, 21: 962-967.PubMedGoogle Scholar
  100. Breier A, Barancik M, Stefankova Z, Uhrik B, Tribulova N: Effect of pentoxifylline on P-glycoprotein mediated vincristine resistance of L1210 mouse leukemic cell line. Neoplasma. 1994, 41: 297-303.PubMedGoogle Scholar
  101. Wigler PW, Patterson FK: Reversal agent inhibition of the multidrug resistance pump in human leukemic lymphoblasts. Biochim Biophys Acta. 1994, 1189: 1-6.PubMedGoogle Scholar
  102. Gruol DJ, Zee MC, Trotter J, Bourgeois S: Reversal of multidrug resistance by RU 486. Cancer Res. 1994, 54: 3088-3091.PubMedGoogle Scholar
  103. Ganapathi R, Hercbergs A, Grabowski D, Ford J: Selective enhancement of vincristine cytotoxicity in multidrug-resistant tumor cells by dilantin (phenytoin). Cancer Res. 1993, 53: 3262-3265.PubMedGoogle Scholar
  104. Hyafil F, Vergely C, Du Vignaud P, Grand-Perret T: In vitro and in vivo reversal of multidrug resistance by GF120918, an acridonecarboxamide derivative. Cancer Res. 1993, 53: 4595-4602.PubMedGoogle Scholar
  105. Callaghan R, Riordan JR: Synthetic and natural opiates interact with P-glycoprotein in multidrug-resistant cells. J Biol Chem. 1993, 268: 16059-16064.PubMedGoogle Scholar
  106. Efferth T, Volm M: Modulation of P-glycoprotein-mediated multidrug resistance by monoclonal antibodies, immunotoxins or antisense oligodeoxynucleotides in kidney carcinoma and normal kidney cells. Oncology. 1993, 50: 303-308.PubMedGoogle Scholar
  107. Kirk J, Houlbrook S, Stuart NS, Stratford IJ, Harris AL, Carmichael J: Selective reversal of vinblastine resistance in multidrug-resistant cell lines by tamoxifen, toremifene and their metabolites. Eur J Cancer. 1993, 29A: 1152-1157.PubMedGoogle Scholar
  108. Miyamoto K, Wakusawa S, Inoko K, Takagi K, Koyama M: Reversal of vinblastine resistance by a new staurosporine derivative, NA-382, in P388/ADR cells. Cancer Lett. 1992, 64: 177-183. 10.1016/0304-3835(92)90079-B.PubMedGoogle Scholar
  109. van Kalken CK, van der Hoeven JJ, de Jong J, Giaccone G, Schuurhuis GJ, Maessen PA, Blokhuis WM, van der Vijgh WJ, Pinedo HM: Bepridil in combination with anthracyclines to reverse anthracycline resistance in cancer patients. Eur J Cancer. 1991, 27: 739-744.PubMedGoogle Scholar
  110. Boesch D, Gaveriaux C, Jachez B, Pourtier-Manzanedo A, Bollinger P, Loor F: In vivo circumvention of P-glycoprotein-mediated multidrug resistance of tumor cells with SDZ PSC 833. Cancer Res. 1991, 51: 4226-4233.PubMedGoogle Scholar
  111. Friche E, Jensen PB, Sehested M, Demant EJ, Nissen NN: The solvents cremophor EL and Tween 80 modulate daunorubicin resistance in the multidrug resistant Ehrlich ascites tumor. Cancer Commun. 1990, 2: 297-303.PubMedGoogle Scholar
  112. Gosland MP, Lum BL, Sikic BI: Reversal by cefoperazone of resistance to etoposide, doxorubicin, and vinblastine in multidrug resistant human sarcoma cells. Cancer Res. 1989, 49: 6901-6905.PubMedGoogle Scholar
  113. Ford JM, Prozialeck WC, Hait WN: Structural features determining activity of phenothiazines and related drugs for inhibition of cell growth and reversal of multidrug resistance. Mol Pharmacol. 1989, 35: 105-115.PubMedGoogle Scholar
  114. Sato S, Watanabe Y, Okamura K, Hamanaka R, Mori T, Kohno K, Kuwano M: Potentiation of vincristine and actinomycin D by a new synthetic imidazole anti-tumor agent YM534 active against human cancer cells and multidrug-resistant cells. Anticancer Drug Des. 1989, 4: 125-135.PubMedGoogle Scholar
  115. Cornwell MM, Pastan I, Gottesman MM: Certain calcium channel blockers bind specifically to multidrug-resistant human KB carcinoma membrane vesicles and inhibit drug binding to P-glycoprotein. J Biol Chem. 1987, 262: 2166-2170.PubMedGoogle Scholar
  116. Twentyman PR, Fox NE, White DJ: Cyclosporin A and its analogues as modifiers of adriamycin and vincristine resistance in a multi-drug resistant human lung cancer cell line. Br J Cancer. 1987, 56: 55-57.PubMed CentralPubMedGoogle Scholar
  117. Chauffert B, Martin M, Hammann A, Michel MF, Martin F: Amiodarone-induced enhancement of doxorubicin and 4'-deoxydoxorubicin cytotoxicity to rat colon cancer cells in vitro and in vivo. Cancer Res. 1986, 46: 825-830.PubMedGoogle Scholar
  118. Tsuruo T, Iida H, Kitatani Y, Yokota K, Tsukagoshi S, Sakurai Y: Effects of quinidine and related compounds on cytotoxicity and cellular accumulation of vincristine and adriamycin in drug-resistant tumor cells. Cancer Res. 1984, 44: 4303-4307.PubMedGoogle Scholar
  119. Tsuruo T, Iida H, Tsukagoshi S, Sakurai Y: Overcoming of vincristine resistance in P388 leukemia in vivo and in vitro through enhanced cytotoxicity of vincristine and vinblastine by verapamil. Cancer Res. 1981, 41: 1967-1972.PubMedGoogle Scholar
  120. Murakami N, Sugimoto M, Morita M, Akiyama S, Kobayashi M: Synthesis and evaluation of 4-deacetoxyagosterol A as an MDR-modulator. Bioorg Med Chem Lett. 2000, 10: 2521-2524. 10.1016/S0960-894X(00)00502-3.PubMedGoogle Scholar
  121. Vezmar M, Georges E: Reversal of MRP-mediated doxorubicin resistance with quinoline-based drugs. Biochem Pharmacol. 2000, 59: 1245-1252. 10.1016/S0006-2952(00)00270-7.PubMedGoogle Scholar
  122. Curtin NJ, Turner DP: Dipyridamole-mediated reversal of multidrug resistance in MRP over-expressing human lung carcinoma cells in vitro. Eur J Cancer. 1999, 35: 1020-1026. 10.1016/S0959-8049(99)00038-6.PubMedGoogle Scholar
  123. Terashi K, Oka M, Soda H, Fukuda M, Kawabata S, Nakatomi K, Shiozawa K, Nakamura T, Tsukamoto K, Noguchi Y, Suenaga M, Tei C, Kohno S: Interactions of ofloxacin and erythromycin with the multidrug resistance protein (MRP) in MRP-overexpressing human leukemia cells. Antimicrob Agents Chemother. 2000, 44: 1697-1700. 10.1128/AAC.44.6.1697-1700.2000.PubMed CentralPubMedGoogle Scholar
  124. Payen L, Delugin L, Courtois A, Trinquart Y, Guillouzo A, Fardel O: Reversal of MRP-mediated multidrug resistance in human lung cancer cells by the antiprogestatin drug RU486. Biochem Biophys Res Commun. 1999, 258: 513-518. 10.1006/bbrc.1999.0671.PubMedGoogle Scholar
  125. Nakamura T, Oka M, Aizawa K, Soda H, Fukuda M, Terashi K, Ikeda K, Mizuta Y, Noguchi Y, Kimura Y, Tsuruo T, Kohno S: Direct interaction between a quinoline derivative, MS-209, and multidrug resistance protein (MRP) in human gastric cancer cells. Biochem Biophys Res Commun. 1999, 255: 618-624. 10.1006/bbrc.1999.0245.PubMedGoogle Scholar
  126. Courtois A, Payen L, Vernhet L, de Vries EG, Guillouzo A, Fardel O: Inhibition of multidrug resistance-associated protein (MRP) activity by rifampicin in human multidrug-resistant lung tumor cells. Cancer Lett. 1999, 139: 97-104. 10.1016/S0304-3835(99)00024-5.PubMedGoogle Scholar
  127. Duffy CP, Elliott CJ, O'Connor RA, Heenan MM, Coyle S, Cleary IM, Kavanagh K, Verhaegen S, O'Loughlin CM, NicAmhlaoibh R, Clynes M: Enhancement of chemotherapeutic drug toxicity to human tumour cells in vitro by a subset of non-steroidal anti-inflammatory drugs (NSAIDs). Eur J Cancer. 1998, 34: 1250-1259. 10.1016/S0959-8049(98)00045-8.PubMedGoogle Scholar
  128. Nagayama S, Chen ZS, Kitazono M, Takebayashi Y, Niwa K, Yamada K, Tani A, Haraguchi M, Sumizawa T, Furukawa T, Aikou T, Akiyama S: Increased sensitivity to vincristine of MDR cells by the leukotriene D4 receptor antagonist, ONO-1078. Cancer Lett. 1998, 130: 175-182. 10.1016/S0304-3835(98)00132-3.PubMedGoogle Scholar
  129. Draper MP, Martell RL, Levy SB: Indomethacin-mediated reversal of multidrug resistance and drug efflux in human and murine cell lines overexpressing MRP, but not P-glycoprotein. Br J Cancer. 1997, 75: 810-815.PubMed CentralPubMedGoogle Scholar
  130. Gollapudi S, Kim CH, Tran BN, Sangha S, Gupta S: Probenecid reverses multidrug resistance in multidrug resistance-associated protein-overexpressing HL60/AR and H69/AR cells but not in P-glycoprotein-overexpressing HL60/Tax and P388/ADR cells. Cancer Chemother Pharmacol. 1997, 40: 150-158. 10.1007/s002800050640.PubMedGoogle Scholar
  131. Manzano RG, Wright KA, Twentyman PR: Modulation by acrolein and chloroacetaldehyde of multidrug resistance mediated by the multidrug resistance-associated protein (MRP). Clin Cancer Res. 1996, 2: 1321-1326.PubMedGoogle Scholar
  132. Vanhoefer U, Cao S, Minderman H, Toth K, Skenderis BS, Slovak ML, Rustum YM: d,l-buthionine-(S,R)-sulfoximine potentiates in vivo the therapeutic efficacy of doxorubicin against multidrug resistance protein-expressing tumors. Clin Cancer Res. 1996, 2: 1961-1968.PubMedGoogle Scholar
  133. Vanhoefer U, Cao S, Minderman H, Toth K, Scheper RJ, Slovak ML, Rustum YM: PAK-104P, a pyridine analogue, reverses paclitaxel and doxorubicin resistance in cell lines and nude mice bearing xenografts that overexpress the multidrug resistance protein. Clin Cancer Res. 1996, 2: 369-377.PubMedGoogle Scholar
  134. Gollapudi S, Thadepalli F, Kim CH, Gupta S: Difloxacin reverses multidrug resistance in HL-60/AR cells that overexpress the multidrug resistance-related protein (MRP) gene. Oncol Res. 1995, 7: 213-225.PubMedGoogle Scholar
  135. Gekeler V, Ise W, Sanders KH, Ulrich WR, Beck J: The leukotriene LTD4 receptor antagonist MK571 specifically modulates MRP associated multidrug resistance. Biochem Biophys Res Commun. 1995, 208: 345-352. 10.1006/bbrc.1995.1344.PubMedGoogle Scholar
  136. Zhang S, Yang X, Morris ME: Flavonoids are inhibitors of breast cancer resistance protein (ABCG2)-mediated transport. Mol Pharmacol. 2004, 65: 1208-1216. 10.1124/mol.65.5.1208.PubMedGoogle Scholar
  137. Imai Y, Tsukahara S, Asada S, Sugimoto Y: Phytoestrogens/Flavonoids Reverse Breast Cancer Resistance Protein/ABCG2-Mediated Multidrug Resistance. Cancer Res. 2004, 64: 4346-4352. 10.1158/0008-5472.CAN-04-0078.PubMedGoogle Scholar
  138. Houghton PJ, Germain GS, Harwood FC, Schuetz JD, Stewart CF, Buchdunger E, Traxler P: Imatinib mesylate is a potent inhibitor of the ABCG2 (BCRP) transporter and reverses resistance to topotecan and SN-38 in vitro. Cancer Res. 2004, 64: 2333-2337. 10.1158/0008-5472.CAN-03-3344.PubMedGoogle Scholar
  139. Sugimoto Y, Tsukahara S, Imai Y, Ueda K, Tsuruo T: Reversal of breast cancer resistance protein-mediated drug resistance by estrogen antagonists and agonists. Mol Cancer Ther. 2003, 2: 105-112.PubMedGoogle Scholar
  140. Allen JD, van Loevezijn A, Lakhai JM, van der Valk M, van Tellingen O, Reid G, Schellens JH, Koomen GJ, Schinkel AH: Potent and specific inhibition of the breast cancer resistance protein multidrug transporter in vitro and in mouse intestine by a novel analogue of fumitremorgin C. Mol Cancer Ther. 2002, 1: 417-425.PubMedGoogle Scholar
  141. de Bruin M, Miyake K, Litman T, Robey R, Bates SE: Reversal of resistance by GF120918 in cell lines expressing the ABC half-transporter, MXR. Cancer Lett. 1999, 146: 117-126. 10.1016/S0304-3835(99)00182-2.PubMedGoogle Scholar
  142. Rabindran SK, He H, Singh M, Brown E, Collins KI, Annable T, Greenberger LM: Reversal of a novel multidrug resistance mechanism in human colon carcinoma cells by fumitremorgin C. Cancer Res. 1998, 58: 5850-5858.PubMedGoogle Scholar
  143. Sharom FJ, Liu R, Qu Q, Romsicki Y: Exploring the structure and function of the P-glycoprotein multidrug transporter using fluorescence spectroscopic tools. Semin Cell Dev Biol. 2001, 12: 257-265. 10.1006/scdb.2000.0251.PubMedGoogle Scholar
  144. Daleke DL: Regulation of transbilayer plasma membrane phospholipid asymmetry. J Lipid Res. 2003, 44: 233-242. 10.1194/jlr.R200019-JLR200.PubMedGoogle Scholar
  145. Wolf DC, Horwitz SB: P-glycoprotein transports corticosterone and is photoaffinity-labeled by the steroid. Int J Cancer. 1992, 52: 141-146.PubMedGoogle Scholar
  146. Liu Y, Huang L, Hoffman T, Gosland M, Vore M: MDR1 substrates/modulators protect against beta-estradiol-17beta-D-glucuronide cholestasis in rat liver. Cancer Res. 1996, 56: 4992-4997.PubMedGoogle Scholar
  147. Ernest S, Bello-Reuss E: Secretion of platelet-activating factor is mediated by MDR1 P-glycoprotein in cultured human mesangial cells. J Am Soc Nephrol. 1999, 10: 2306-2313.PubMedGoogle Scholar
  148. Liu XD, Liu GQ: P glycoprotein regulated transport of glutamate at blood brain barrier. Acta Pharmacol Sin. 2001, 22: 111-116.PubMedGoogle Scholar
  149. King M, Su W, Chang A, Zuckerman A, Pasternak GW: Transport of opioids from the brain to the periphery by P-glycoprotein: peripheral actions of central drugs. Nat Neurosci. 2001, 4: 268-274. 10.1038/85115.PubMedGoogle Scholar
  150. Vogelgesang S, Cascorbi I, Schroeder E, Pahnke J, Kroemer HK, Siegmund W, Kunert-Keil C, Walker LC, Warzok RW: Deposition of Alzheimer's beta-amyloid is inversely correlated with P-glycoprotein expression in the brains of elderly non-demented humans. Pharmacogenetics. 2002, 12: 535-541. 10.1097/00008571-200210000-00005.PubMedGoogle Scholar
  151. Lam FC, Liu R, Lu P, Shapiro AB, Renoir JM, Sharom FJ, Reiner PB: beta-Amyloid efflux mediated by p-glycoprotein. J Neurochem. 2001, 76: 1121-1128. 10.1046/j.1471-4159.2001.00113.x.PubMedGoogle Scholar
  152. Leier I, Jedlitschky G, Buchholz U, Cole SP, Deeley RG, Keppler D: The MRP gene encodes an ATP-dependent export pump for leukotriene C4 and structurally related conjugates. J Biol Chem. 1994, 269: 27807-27810.PubMedGoogle Scholar
  153. Jedlitschky G, Leier I, Buchholz U, Barnouin K, Kurz G, Keppler D: Transport of glutathione, glucuronate, and sulfate conjugates by the MRP gene-encoded conjugate export pump. Cancer Res. 1996, 56: 988-994.PubMedGoogle Scholar
  154. Loe DW, Stewart RK, Massey TE, Deeley RG, Cole SP: ATP-dependent transport of aflatoxin B1 and its glutathione conjugates by the product of the multidrug resistance protein (MRP) gene. Mol Pharmacol. 1997, 51: 1034-1041.PubMedGoogle Scholar
  155. Krishnamurthy P, Ross DD, Nakanishi T, Bailey-Dell K, Zhou S, Mercer KE, Sarkadi B, Sorrentino BP, Schuetz JD: The stem cell marker Bcrp/ABCG2 enhances hypoxic cell survival through interactions with heme. J Biol Chem. 2004, 279: 24218-24225. 10.1074/jbc.M313599200.PubMedGoogle Scholar
  156. Tsuruoka S, Sugimoto KI, Fujimura A, Imai M, Asano Y, Muto S: P-glycoprotein-mediated drug secretion in mouse proximal tubule perfused in vitro. J Am Soc Nephrol. 2001, 12: 177-181. 10.1159/000051255.PubMedGoogle Scholar
  157. Malingre MM, Beijnen JH, Schellens JH: Oral delivery of taxanes. Invest New Drugs. 2001, 19: 155-162. 10.1023/A:1010635000879.PubMedGoogle Scholar
  158. Mickley LA, Lee JS, Weng Z, Zhan Z, Alvarez M, Wilson W, Bates SE, Fojo T: Genetic polymorphism in MDR-1: a tool for examining allelic expression in normal cells, unselected and drug-selected cell lines, and human tumors. Blood. 1998, 91: 1749-1756.PubMedGoogle Scholar
  159. Fromm MF: The influence of MDR1 polymorphisms on P-glycoprotein expression and function in humans. Adv Drug Deliv Rev. 2002, 54: 1295-1310. 10.1016/S0169-409X(02)00064-9.PubMedGoogle Scholar
  160. Brinkmann U, Eichelbaum M: Polymorphisms in the ABC drug transporter gene MDR1. Pharmacogenomics J. 2001, 1: 59-64.PubMedGoogle Scholar
  161. Ito S, Ieiri I, Tanabe M, Suzuki A, Higuchi S, Otsubo K: Polymorphism of the ABC transporter genes, MDR1, MRP1 and MRP2/cMOAT, in healthy Japanese subjects. Pharmacogenetics. 2001, 11: 175-184. 10.1097/00008571-200103000-00008.PubMedGoogle Scholar
  162. Kerb R, Hoffmeyer S, Brinkmann U: ABC drug transporters: hereditary polymorphisms and pharmacological impact in MDR1, MRP1 and MRP2. Pharmacogenomics. 2001, 2: 51-64. 10.1517/14622416.2.1.51.PubMedGoogle Scholar
  163. Moriya Y, Nakamura T, Horinouchi M, Sakaeda T, Tamura T, Aoyama N, Shirakawa T, Gotoh A, Fujimoto S, Matsuo M, Kasuga M, Okumura K: Effects of polymorphisms of MDR1, MRP1, and MRP2 genes on their mRNA expression levels in duodenal enterocytes of healthy Japanese subjects. Biol Pharm Bull. 2002, 25: 1356-1359. 10.1248/bpb.25.1356.PubMedGoogle Scholar
  164. Tian R, Koyabu N, Takanaga H, Matsuo H, Ohtani H, Sawada Y: Effects of grapefruit juice and orange juice on the intestinal efflux of P-glycoprotein substrates. Pharm Res. 2002, 19: 802-809. 10.1023/A:1016100715125.PubMedGoogle Scholar
  165. Kurata Y, Ieiri I, Kimura M, Morita T, Irie S, Urae A, Ohdo S, Ohtani H, Sawada Y, Higuchi S, Otsubo K: Role of human MDR1 gene polymorphism in bioavailability and interaction of digoxin, a substrate of P-glycoprotein. Clin Pharmacol Ther. 2002, 72: 209-219. 10.1067/mcp.2002.126177.PubMedGoogle Scholar
  166. Hennessy M, Kelleher D, Spiers JP, Barry M, Kavanagh P, Back D, Mulcahy F, Feely J: St Johns wort increases expression of P-glycoprotein: implications for drug interactions. Br J Clin Pharmacol. 2002, 53: 75-82. 10.1046/j.0306-5251.2001.01516.x.PubMed CentralPubMedGoogle Scholar
  167. Kastin AJ, Fasold MB, Zadina JE: Endomorphins, Met-enkephalin, Tyr-MIF-1, and the P-glycoprotein efflux system. Drug Metab Dispos. 2002, 30: 231-234. 10.1124/dmd.30.3.231.PubMedGoogle Scholar
  168. Kawahara M, Sakata A, Miyashita T, Tamai I, Tsuji A: Physiologically based pharmacokinetics of digoxin in mdr1a knockout mice. J Pharm Sci. 1999, 88: 1281-1287. 10.1021/js9901763.PubMedGoogle Scholar
  169. Miyama T, Takanaga H, Matsuo H, Yamano K, Yamamoto K, Iga T, Naito M, Tsuruo T, Ishizuka H, Kawahara Y, Sawada Y: P-glycoprotein-mediated transport of itraconazole across the blood-brain barrier. Antimicrob Agents Chemother. 1998, 42: 1738-1744.PubMed CentralPubMedGoogle Scholar
  170. Mayer U, Wagenaar E, Dorobek B, Beijnen JH, Borst P, Schinkel AH: Full blockade of intestinal P-glycoprotein and extensive inhibition of blood-brain barrier P-glycoprotein by oral treatment of mice with PSC833. J Clin Invest. 1997, 100: 2430-2436.PubMed CentralPubMedGoogle Scholar
  171. Schinkel AH, Smit JJ, van Tellingen O, Beijnen JH, Wagenaar E, van Deemter L, Mol CA, van der Valk MA, Robanus-Maandag EC, te Riele HP: Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs. Cell. 1994, 77: 491-502. 10.1016/0092-8674(94)90212-7.PubMedGoogle Scholar
  172. Jonker JW, Smit JW, Brinkhuis RF, Maliepaard M, Beijnen JH, Schellens JH, Schinkel AH: Role of breast cancer resistance protein in the bioavailability and fetal penetration of topotecan. J Natl Cancer Inst. 2000, 92: 1651-1656. 10.1093/jnci/92.20.1651.PubMedGoogle Scholar
  173. Hyde SC, Emsley P, Hartshorn MJ, Mimmack MM, Gileadi U, Pearce SR, Gallagher MP, Gill DR, Hubbard RE, Higgins CF: Structural model of ATP-binding proteins associated with cystic fibrosis, multidrug resistance and bacterial transport. Nature. 1990, 346: 362-365. 10.1038/346362a0.PubMedGoogle Scholar
  174. Sonveaux N, Shapiro AB, Goormaghtigh E, Ling V, Ruysschaert JM: Secondary and tertiary structure changes of reconstituted P-glycoprotein. A Fourier transform attenuated total reflection infrared spectroscopy analysis. J Biol Chem. 1996, 271: 24617-24624. 10.1074/jbc.271.40.24617.PubMedGoogle Scholar
  175. Rosenberg MF, Velarde G, Ford RC, Martin C, Berridge G, Kerr ID, Callaghan R, Schmidlin A, Wooding C, Linton KJ, Higgins CF: Repacking of the transmembrane domains of P-glycoprotein during the transport ATPase cycle. Embo J. 2001, 20: 5615-5625. 10.1093/emboj/20.20.5615.PubMed CentralPubMedGoogle Scholar
  176. Rosenberg MF, Kamis AB, Callaghan R, Higgins CF, Ford RC: Three-dimensional structures of the mammalian multidrug resistance P-glycoprotein demonstrate major conformational changes in the transmembrane domains upon nucleotide binding. J Biol Chem. 2003, 278: 8294-8299. 10.1074/jbc.M211758200.PubMedGoogle Scholar
  177. Rosenberg MF, Callaghan R, Ford RC, Higgins CF: Structure of the multidrug resistance P-glycoprotein to 2.5 nm resolution determined by electron microscopy and image analysis. J Biol Chem. 1997, 272: 10685-10694. 10.1074/jbc.272.3.1665.PubMedGoogle Scholar
  178. Senior AE, Bhagat S: P-glycoprotein shows strong catalytic cooperativity between the two nucleotide sites. Biochemistry. 1998, 37: 831-836. 10.1021/bi9719962.PubMedGoogle Scholar
  179. Loo TW, Bartlett MC, Clarke DM: Drug binding in human P-glycoprotein causes conformational changes in both nucleotide-binding domains. J Biol Chem. 2003, 278: 1575-1578. 10.1074/jbc.M211307200.PubMedGoogle Scholar
  180. Gao M, Cui HR, Loe DW, Grant CE, Almquist KC, Cole SP, Deeley RG: Comparison of the functional characteristics of the nucleotide binding domains of multidrug resistance protein 1. J Biol Chem. 2000, 275: 13098-13108. 10.1074/jbc.275.17.13098.PubMedGoogle Scholar
  181. Loo TW, Clarke DM: Identification of residues within the drug-binding domain of the human multidrug resistance P-glycoprotein by cysteine-scanning mutagenesis and reaction with dibromobimane. J Biol Chem. 2000, 275: 39272-39278. 10.1074/jbc.M007741200.PubMedGoogle Scholar
  182. Loo TW, Clarke DM: The transmembrane domains of the human multidrug resistance P-glycoprotein are sufficient to mediate drug binding and trafficking to the cell surface. J Biol Chem. 1999, 274: 24759-24765. 10.1074/jbc.274.35.24759.PubMedGoogle Scholar
  183. Consoli U, Priebe W, Ling YH, Mahadevia R, Griffin M, Zhao S, Perez-Soler R, Andreeff M: The novel anthracycline annamycin is not affected by P-glycoprotein-related multidrug resistance: comparison with idarubicin and doxorubicin in HL-60 leukemia cell lines. Blood. 1996, 88: 633-644.PubMedGoogle Scholar
  184. Perez-Soler R, Neamati N, Zou Y, Schneider E, Doyle LA, Andreeff M, Priebe W, Ling YH: Annamycin circumvents resistance mediated by the multidrug resistance-associated protein (MRP) in breast MCF-7 and small-cell lung UMCC-1 cancer cell lines selected for resistance to etoposide. Int J Cancer. 1997, 71: 35-41. 10.1002/(SICI)1097-0215(19970328)71:1<35::AID-IJC8>3.0.CO;2-4.PubMedGoogle Scholar
  185. Mazel M, Clair P, Rousselle C, Vidal P, Scherrmann JM, Mathieu D, Temsamani J: Doxorubicin-peptide conjugates overcome multidrug resistance. Anticancer Drugs. 2001, 12: 107-116. 10.1097/00001813-200102000-00003.PubMedGoogle Scholar
  186. Belpomme D, Gauthier S, Pujade-Lauraine E, Facchini T, Goudier MJ, Krakowski I, Netter-Pinon G, Frenay M, Gousset C, Marie FN, Benmiloud M, Sturtz F: Verapamil increases the survival of patients with anthracycline-resistant metastatic breast carcinoma. Ann Oncol. 2000, 11: 1471-1476. 10.1023/A:1026556119020.PubMedGoogle Scholar
  187. Haussermann K, Benz B, Gekeler V, Schumacher K, Eichelbaum M: Effects of verapamil enantiomers and major metabolites on the cytotoxicity of vincristine and daunomycin in human lymphoma cell lines. Eur J Clin Pharmacol. 1991, 40: 53-59. 10.1007/BF00315139.PubMedGoogle Scholar
  188. Teodori E, Dei S, Scapecchi S, Gualtieri F: The medicinal chemistry of multidrug resistance (MDR) reversing drugs. Farmaco. 2002, 57: 385-415. 10.1016/S0014-827X(02)01229-6.PubMedGoogle Scholar
  189. Toffoli G, Simone F, Corona G, Raschack M, Cappelletto B, Gigante M, Boiocchi M: Structure-activity relationship of verapamil analogs and reversal of multidrug resistance. Biochem Pharmacol. 1995, 50: 1245-1255. 10.1016/0006-2952(95)02003-U.PubMedGoogle Scholar
  190. Slater LM, Sweet P, Stupecky M, Gupta S: Cyclosporin A reverses vincristine and daunorubicin resistance in acute lymphatic leukemia in vitro. J Clin Invest. 1986, 77: 1405-1408.PubMed CentralPubMedGoogle Scholar
  191. Arceci RJ, Stieglitz K, Bierer BE: Immunosuppressants FK506 and rapamycin function as reversal agents of the multidrug resistance phenotype. Blood. 1992, 80: 1528-1536.PubMedGoogle Scholar
  192. Fracasso PM, Brady MF, Moore DH, Walker JL, Rose PG, Letvak L, Grogan TM, McGuire WP: Phase II study of paclitaxel and valspodar (PSC 833) in refractory ovarian carcinoma: a gynecologic oncology group study. J Clin Oncol. 2001, 19: 2975-2982.PubMedGoogle Scholar
  193. Mistry P, Stewart AJ, Dangerfield W, Okiji S, Liddle C, Bootle D, Plumb JA, Templeton D, Charlton P: In vitro and in vivo reversal of P-glycoprotein-mediated multidrug resistance by a novel potent modulator, XR9576. Cancer Res. 2001, 61: 749-758.PubMedGoogle Scholar
  194. Dayan G, Jault JM, Baubichon-Cortay H, Baggetto LG, Renoir JM, Baulieu EE, Gros P, Di Pietro A: Binding of steroid modulators to recombinant cytosolic domain from mouse P-glycoprotein in close proximity to the ATP site. Biochemistry. 1997, 36: 15208-15215. 10.1021/bi9718696.PubMedGoogle Scholar
  195. Conseil G, Baubichon-Cortay H, Dayan G, Jault JM, Barron D, Di Pietro A: Flavonoids: a class of modulators with bifunctional interactions at vicinal ATP- and steroid-binding sites on mouse P-glycoprotein. Proc Natl Acad Sci U S A. 1998, 95: 9831-9836. 10.1073/pnas.95.17.9831.PubMed CentralPubMedGoogle Scholar
  196. Rabindran SK, Ross DD, Doyle LA, Yang W, Greenberger LM: Fumitremorgin C reverses multidrug resistance in cells transfected with the breast cancer resistance protein. Cancer Res. 2000, 60: 47-50.PubMedGoogle Scholar

Copyright

© Choi; licensee BioMed Central Ltd. 2005

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Advertisement